Exiqon
Supplier of flexible solutions for RNA research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
DKK683m Valuation: DKK683m 5.4x EV/Revenue -20.2x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | 7 % | - | - |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | 4 % | - | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
| R&D % of revenue | 23 % | - | - |
Source: Company filings or news article
Related Content
Exiqon specializes in providing advanced RNA research tools and services, catering to researchers and pharmaceutical companies. Operating in the biotechnology market, Exiqon offers a range of products and services such as RNA isolation, sequencing, quantitative real-time PCR (qPCR), microarray analysis, and in situ hybridization. The company's business model revolves around selling these specialized tools and offering custom services to meet the unique needs of their clients. Revenue is generated through the sale of products and the provision of custom research services. Exiqon's clients primarily include academic researchers, biotech firms, and pharmaceutical companies looking for reliable and specific RNA analysis solutions.
Keywords: RNA research, sequencing, qPCR, microarray, in situ hybridization, biotechnology, custom services, pharmaceutical, academic research, RNA isolation.